17 research outputs found
Application of a simplified probe feed impedance formula to the design of a dual frequency patch antenna
A simplified probe feed input impedance for a rectangular patch antenna based on the Green's function is used to design a dual frequency matched antenna. The predicted results at design frequencies of 1.9 and 2.4 GHz are in close agreement with experimental measurements
Sources of activator Ca2plus for galanin-induced contractions of rat gastric fundus, jejunum and colon
Actions of several substituted short analogues of porcine galanin on isolated rat fundus strips: a structure-activity relationship
Increased potency of some substituted short peptide analogues in comparison to galanin(1-15)-NH2in rat fundus strips
Principios biofisicos de la dialisis
Background
This two-stage, phase IIa study investigated the antitumor activity and safety of MOR208, an Fc-engineered, humanized, CD19 antibody, in patients with relapsed or refractory (R-R) B-cell non-Hodgkinâs lymphoma (NHL). CD19 is broadly expressed across the B-lymphocyte lineage, including in B-cell malignancies, but not by hematological stem cells.
Patients and methods
Patients agedâ
â„18â
years, with R-R NHL progressing afterâ
â„1 prior rituximab-containing regimen were enrolled into subtype-specific cohorts: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), other indolent (i)NHL and mantle cell lymphoma (MCL). Treatment was MOR208, 12â
mg/kg intravenously, weekly, for 8â
weeks. Patients with at least stable disease could continue treatment for an additional 4â
weeks. Those with a partial or complete response after 12â
weeks could receive extended MOR208 treatment (12â
mg/kg, either monthly or every second week) until progression. The primary end point was overall response rate.
Results
Ninety-two patients were enrolled: DLBCL (nâ
=â
35), FL (nâ
=â
34), other iNHL (nâ
=â
11) and MCL (nâ
=â
12). Responses were observed in DLBCL, FL and other iNHL cohorts (26%, 29% and 27%, respectively). They lastedâ
â„12â
months in 5/9 responding patients with DLBCL, 4/9 with FL and 2/3 with other iNHL. Responses in nine patients are ongoing (>26â
months in five instances). Patients with rituximab refractory disease showed a similar response rate and progression-free survival time to patients with non-refractory disease. The most common adverse events (any grade) were infusion-related reactions (12%) and neutropenia (12%). One patient experienced a grade 4 infusion-related reaction and eight patients (9%) experienced grade 3/4 neutropenia. No treatment-related deaths were reported.
Conclusions
MOR208 monotherapy demonstrated promising clinical activity in patients with R-R DLBCL and R-R FL, including in patients with rituximab refractory tumors. These efficacy data and the favorable safety profile support further investigation of MOR208 in phase II/III combination therapy trials in R-R DLBCL